芹菜素通过下调HK-2表达抑制非小细胞肺癌H460细胞糖酵解和球形成

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (3706 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate whether apigenin (API) inhibits the glycolysis and self-renewal capacity by downregulating the expression of glucose metabolism related kinase HK-2 in non-small cell lung cancer (NSCLC) H460 cells in vitro. Methods H460 cells were transfected with HK-2 cDNA, treated with sub-cytotoxicity concentrations of API (20 μM; 40 μM and 80 μM) or in combination with API (80 μM) treatment and HK-2 cDNA transfection. Western blot was utilized to detect the expression of HK-2. The levels of lactate production and glucose consumption were using measurement of lactate production and glucose consumption assays. The spheroid formation assay was employed to detect the self-renewal capacity in H460 cells. Results The sub-cytotoxic concentrations of API decreased the expression of glucose metabolism related kinase HK-2 and reduced lactiate production and glucose consumption, as well as decreased sphere formation rate in NSCLC H460 cells in a dose-dependent tendency. Moreover, overexpression of HK-2 could rescue the inhibitory effects of API on lactate production, glucose consumption and spheroid formation in NSCLC H460 cells. Conclusion API can inhibit glycolysis and self-renewal capacity by downregulating HK-2 expression in NSCLC H460 cells.

Key words： non-small cell lung cancer apigenin HK-2 glycolysis self renewal

Received: 15 December 2022

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Fei
	YUAN Qing
	ZHANG Jiansong

Cite this article:

SUN Fei,YUAN Qing,ZHANG Jiansong. Apigenin Inhibits Glycolysis and Spheroid Formation via Downregulation of HK-2 Expression in Non-Small Cell Lung Cancer H460 Cells[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(1): 1-5.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I1/1

[1] Siegel R L, Miller K D, Jemal A.Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
[2] Chansky K, Detterbeck F C, Nicholson A G, et al.The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2017, 12(7): 1109-1121.
[3] Koppenol W H, Bounds P L, Dang C V.Otto Warburg’s contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11(5): 325-37.
[4] Chen L, Lin X, Lei Y, et al.Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-kappaBp65/HK2 signalling[J]. J Exp Clin Cancer Res, 2022, 41(1): 329.
[5] Zhang T, Zhu X, Wu H, et al.Targeting the ROS/PI3K/AKT/HIF-1alpha/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2-Deoxy-d-glucose[J]. J Cell Mol Med, 2019, 23(5): 3711-3723.
[6] Li R, Mei S, Ding Q, et al.A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors[J]. Sci Rep, 2022, 12(1): 18807.
[7] Wang J, Shao F, Yang Y, et al.A non-metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11-mediated CD133 stability[J]. Cancer Commun (Lond), 2022, 42(10): 1008-1027.
[8] Adel M, Zahmatkeshan M, Akbarzadeh A, et al.Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles[J]. Biotechnol Rep (Amst), 2022, 34: e00730.
[9] Xu L, Zhang Y, Tian K, et al.Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects[J]. J Exp Clin Cancer Res, 2018, 37(1): 261.
[10] 舒玲, 袁庆, 崔迎红, et al.芹菜素对NCI-H446细胞系球细胞自我更新和uPAR表达的影响[J]. 中南大学学报 (医学版), 2016, 41(11): 1124-1127.
[11] Mahbub A A, Le Maitre C L, Cross N A, et al. The effect of apigenin and chemotherapy combination treatments on apoptosis-related genes and proteins in acute leukaemia cell lines[J]. Sci Rep, 2022, 12(1): 8858.
[12] Zhao Y, Huang H, Jia C H, et al.Apigenin increases radiosensitivity of glioma stem cells by attenuating HIF-1alpha-mediated glycolysis[J]. Med Oncol, 2021, 38(11): 131.
[13] Wang C, Wu Y, Shao J, et al.Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer[J]. BMC Cancer, 2020, 20(1): 150.
[14] Peppicelli S, Bianchini F, Calorini L.Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy[J]. Cancer Metastasis Rev, 2014, 33(2-3): 823-832.
[15] 刘丽华, 孙菲, 周志凌, 等. 芹菜素经上调miR148a-3p表达抑制MHCC97H细胞迁移和侵袭[J]. 湖南师范大学学报 (医学版), 2021, 18(06): 7-9.
[16] 姜素芳, 许畅, 陈阿, 等. 芹菜素对肝细胞癌SMMC-7721细胞系干样细胞自我更新及CK2α表达的影响[J]. 湖南师范大学学报 (医学版), 2017, 14(05): 1-3.
[17] Zhou Z, Tang M, Liu Y, et al.Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line[J]. Anticancer Drugs, 2017, 28(4): 446-456.
[18] Masuelli L, Benvenuto M, Mattera R, et al.In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma[J]. Front Pharmacol, 2017, 8: 373.
[19] Cao H H, Chu J H, Kwan H Y, et al.Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma[J]. Sci Rep, 2016, 6: 21731.
[20] Xu M, Wang S, Song Y U, et al.Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/beta-catenin signaling pathway[J]. Oncol Lett, 2016, 11(5): 3075-3080.
[21] Shukla S, Gupta S.Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells[J]. Cell Cycle, 2007, 6(9): 1102-1114.
[22] Mathupala S P, Ko Y H, Pedersen P L.Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria[J]. Oncogene, 2006, 25(34): 4777-4786.
[23] Xue Y N, Yu B B, Li J L, et al.Zinc and p53 disrupt mitochondrial binding of HK2 by phosphorylating VDAC1[J]. Exp Cell Res, 2019, 374(1): 249-258.
[24] Peschiaroli A, Giacobbe A, Formosa A, et al.miR-143 regulates hexokinase 2 expression in cancer cells[J]. Oncogene, 2013, 32(6): 797-802.
[25] Jiang S, Zhang L F, Zhang H W, et al.A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells[J]. EMBO J, 2012, 31(8): 1985-1998.
[26] 游启爱, 卓文磊, 陈正堂. 己糖激酶2在NSCLC厄洛替尼耐药中的作用及机制[J]. 第三军医大学学报, 2020, 42(05): 453-459.
[27] 祝志强. 宫颈鳞癌患者己糖激酶2和丙酮酸激酶2的高表达与其发生放疗抵抗的关系[J]. 当代医药论丛, 2019, 17(09): 61-62.
[28] Vartanian A, Agnihotri S, Wilson M R, et al.Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma[J]. Oncotarget, 2016, 7(43): 69518-69535.
[29] Song K, Li M, Xu X, et al.Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia[J]. Oncol Lett, 2016, 12(1): 334-342.